Pfizer Starts Early-Stage Study Of Oral Antiviral COVID-19 Drug
Pfizer Starts Early-Stage Study Of Oral Antiviral COVID-19 Drug
辉瑞公司开始口服抗病毒新冠肺炎药物的早期研究
Pfizer Inc (NYSE: PFE) has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy, dubbed as PF-07321332.
- The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SE (NASDAQ: BNTX), said the antiviral candidate showed potent activity against SARS-CoV-2 in lab studies.
- The Phase 1 study progressed to multiple ascending doses after completing the dosing of single ascending doses in healthy adults.
- PF-07321332 is a protease inhibitor that prevents the virus from replicating in cells.
- The company is also studying an intravenously administered antiviral candidate in an early-stage trial in hospitalized COVID-19 patients.
- Pfizer's candidate is behind two other oral antiviral therapies, which are in mid-stage trials:
- Molnupiravir - in development by Merck & Co (NYSE: MRK) with Ridgeback Bio. Recent interim data showed that the antiviral significantly reduced the infectious virus in COVID-19 patients after five treatment days.
- Roche Holdings AG (OTC:RHHBY) and Atea Pharmaceuticals Inc (NASDAQ: AVIR) are developing AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The first patient was dosed in February.
- Gilead Sciences' remdesivir is currently the only FDA-approved drug for the treatment of COVID-19.
- The FDA granted an emergency authorization to intravenous therapies from Eli Lilly bamlanivimab alone and in combination with etesevimab, and a combination therapy from Regeneron.
- Price Action: PFE shares are trading 0.97% lower at $35.65 in market hours on the last check Tuesday.
Pfizer Inc (NYSE: PFE) has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy, dubbed as PF-07321332.
辉瑞公司(纽约证券交易所代码:PFE)已经开始在美国进行名为PF-07321332的口服新冠肺炎抗病毒疗法的早期试验。
- The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SE (NASDAQ: BNTX), said the antiviral candidate showed potent activity against SARS-CoV-2 in lab studies.
- The Phase 1 study progressed to multiple ascending doses after completing the dosing of single ascending doses in healthy adults.
- PF-07321332 is a protease inhibitor that prevents the virus from replicating in cells.
- The company is also studying an intravenously administered antiviral candidate in an early-stage trial in hospitalized COVID-19 patients.
- Pfizer's candidate is behind two other oral antiviral therapies, which are in mid-stage trials:
- Molnupiravir - in development by Merck & Co (NYSE: MRK) with Ridgeback Bio. Recent interim data showed that the antiviral significantly reduced the infectious virus in COVID-19 patients after five treatment days.
- Roche Holdings AG (OTC:RHHBY) and Atea Pharmaceuticals Inc (NASDAQ: AVIR) are developing AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The first patient was dosed in February.
- Gilead Sciences' remdesivir is currently the only FDA-approved drug for the treatment of COVID-19.
- The FDA granted an emergency authorization to intravenous therapies from Eli Lilly bamlanivimab alone and in combination with etesevimab, and a combination therapy from Regeneron.
- Price Action: PFE shares are trading 0.97% lower at $35.65 in market hours on the last check Tuesday.
- 这家制药商与德国生物科技公司(纳斯达克股票代码:BNTX)合作开发了美国第一个授权的新冠肺炎疫苗,该公司表示,这种抗病毒候选药物在实验室研究中显示出对SARS-CoV-2的强大活性。
- 第一阶段研究在健康成年人完成单次递增剂量后进行到多个递增剂量。
- PF-07321332是一种蛋白酶抑制剂,可以阻止病毒在细胞内复制。
- 该公司还在研究一种静脉注射的抗病毒候选药物,用于住院的新冠肺炎患者的早期试验。
- 辉瑞的候选人是另外两种口服抗病毒疗法的幕后推手,这两种疗法正在进行中期试验:
- Molnupiravir-由默克公司(纽约证券交易所代码:MRK)与Ridgeback Bio共同开发。最近的中期数据显示,抗病毒药物在治疗5天后显著降低了新冠肺炎患者的感染性病毒。
- 罗氏控股公司(场外交易代码:RHHBY)和ATEA制药公司(纳斯达克市场代码:AVIR)正在门诊环境下为轻度或中度新冠肺炎患者开发AT-527型药物。第一名患者在2月份接受了药物治疗。
- 吉利德科学公司的瑞德维韦目前是美国食品和药物管理局批准的唯一一种治疗新冠肺炎的药物。
- FDA批准了礼来公司Bamlanivimab单独和与etesevimab联合使用的静脉治疗,以及Regeneron的联合治疗。
- 价格行动:在周二的最后一次检查中,PFE股价在市场时段下跌0.97%,至35.65美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧
点击这里分享给好友
暂无评论,快来抢沙发吧!